Arvinas, Inc.

ARVN

NASDAQ

Healthcare

Biotechnology

New Haven, CT, US430 employeesarvinas.com

$10.83

-0.50(-4.4%)

52W $6.07 – $13.83

AI-generated

Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins.

Revenue breakdown: Reportable Segment (100%).

$696MMkt Cap

$260MRev TTM

-$80MNI TTM

-8.3xP/E TTM

Latest Earnings

10-K

FY FY2025Feb 23, 2026

10-K for FY2025 was filed on 2026-02-24. AI summary is not available yet.

Read full analysis View SEC Filing

What Changed Recently

Financial Results

Feb 23, 2026

Results of Operations and Financial Condition. On February 24, 2026 , Arvinas, Inc. announced its financial results for the fourth quarter and year ended Decemb

View filing →

Management Change

Feb 11, 2026

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Change in Pre

View filing →

View all recent events →

Fundamentals

How The Business Makes Money

Revenue by Segment

Reportable Segment100%($605M)

Analyst View

Peer Companies

Company	Price	Change	Market Cap	P/E
ERASErasca, Inc.	$17.79	+7.14%	$5.5B	-32.6
DAWNDay One Biopharmaceutical...	$21.46	+0.21%	$2.2B	-20.6
IOVAIovance Biotherapeutics, ...	$3.43	-0.58%	$1.1B	-3.8
AVBPArriVent BioPharma, Inc. ...	$24.68	+1.90%	$1.1B	-5.1
GERNGeron Corporation	$1.66	-0.30%	$1.1B	-12.0
MGTXMeiraGTx Holdings plc	$9.18	+0.94%	$739M	-3.7
ATXSATXS	$12.58	+0.00%	$718M	—
REPLReplimune Group, Inc.	$8.27	+8.61%	$682M	-2.0

Company Profile

CIK0001655759

ISINUS04335A1051

CUSIP04335A105

Phone203 535 1456

Address5 Science Park, New Haven, CT, 06511, US

SEC EDGAR